Literature DB >> 7353353

Metabolism of vasoactive hormones in human isolated lung.

F Al-Ubaidi, Y S Bakhle.   

Abstract

1. The metabolism of some vasoactive hormones perfused through pulmonary vessels was studied in samples of human lung obtained at operations. 2. 5-Hydroxytryptamine was inactivated and this inactivation was inhibited by desmehtylimipramine and mebanazine. 3. Beta-[14C]Phenylethylamine was also metabolized in human lung. 4. Prostaglandin E2 was inactivated and this inactivation inhibited by bromocresol green and frusemide. 5. About 10% of the radioactivity from infused [14C]arachidonic acid emerged from the lung and a small amount of biological activation occurred. 6. Of [14C]arachidonic acid retained by the lung, most was present in phopholipid with lesser amounts in neutral lipid and free acid fractions. 7. The fate of the hormones studied was qualitatively similar to their fate in animal lungs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7353353     DOI: 10.1042/cs0580045

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

Review 1.  The biochemical properties of the pulmonary circulation.

Authors:  J A Pang; D M Geddes
Journal:  Lung       Date:  1981       Impact factor: 2.584

2.  Inhibitors of prostaglandin dehydrogenase (Ph CL 28A and Ph CK 61A) increase output of prostaglandins from rat isolated lung.

Authors:  Y S Bakhle; J J Pankhania
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

3.  Catecholamine effects on pulmonary blood vessels in strangulation.

Authors:  T Kita
Journal:  Z Rechtsmed       Date:  1987

4.  Inhibition by clinically used dyes of prostaglandin inactivation in rat and human lung.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  1981-04       Impact factor: 8.739

5.  The Role of Serotonin Transporter in Human Lung Development and in Neonatal Lung Disorders.

Authors:  E C C Castro; P Sen; W T Parks; C Langston; C Galambos
Journal:  Can Respir J       Date:  2017-02-20       Impact factor: 2.409

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.